全部

1·In postmenopausal women, risk was associated with higher TZD dose.

绝经后女性骨折风险与服用大剂量tzd有关。

2·Treatments used in the control groups included placebo, usual care, and non-TZD antidiabetic therapies.

控制组的治疗方案包括安慰剂，常规护理和非噻唑啉二酮类药物抗糖尿病治疗。

3·The adjusted hazard ratios associated with TZD use were 1.0 for HF hospitalization and 0.98 for mortality.

应用TZDs的患者，心衰住院的调整危险比为1.0，心衰死亡率的调整危险比为0.98。

4·The team reports that there was no significant difference in risk for bladder cancer between TZD and SU users.

研究小组报告，未发现膀胱癌与TZD或SU使用者之间发生风险有显著区别。

5·Those who initiated TZD therapy more than 5 years previously were more than twice as likely to develop bladder cancer than those who initiated SU therapy at the same time point.

之前起始TZD治疗超过5年的患者，与同样时间点起始SU治疗的患者相比，发生膀胱癌的风险增加超过2倍。

6·Those who initiated TZD therapy 5 years or more previously were at more than three times the risk for bladder cancer than those who had started treatment less than 1 year earlier.

起始tzd治疗达5年或以上的患者，与起始治疗少于1年的相比，发生膀胱癌的风险增加超过3倍。

7·At a patient care level, one needs to consider that for a patient at a high risk of fracture or prior knowledge of that possibility, great caution should be taken in using a TZD medication.

在患者护理水平上，对处于骨折高风险或先前知道这种可能性的患者，医生需要考虑这一点，在应用TZD类药物上应十分谨慎。